autism, blindness, cancer, cerebral palsy, diabetes etc. Key biopharmaceutical companies are
majorly investing in research for cell therapy. For instance, Longeveron LL, a biopharmaceutical
company received a US$ 750,000 grant from the Maryland Technology Development Corporation
(TEDCO) in 2018 for stem cell therapy research. These collaborations and government funding are
boosting growth of the cell therapy manufacturing market. However, the strict regulations,
guidelines, and various health safety concerns over cell therapy treatment are restraining growth of
the cell therapy market.
Cell Therapy Manufacturing Market - Regional Insights
On the basis of the region, the global cell therapy market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position
in the global cell therapy manufacturing market, owing to large number of surgeries performed in
the region as well as development of technologically advanced products for therapy. According to
the National Health Statistics Report by the Centers for Disease Control & Prevention (CDC),
around 201,748.3 million surgical and non-surgical procedures were performed in the U.S. in 2011.
Furthermore, Asia Pacific is projected to witness significant growth in the global cell therapy
manufacturing market in the near future. Marginal market share would be grabbed by the local
players entering into market due to less stringent regulatory requirements and growing customer
pool prone to various chronic and infectious disease such as cancer, HIV, hepatitis etc. Therefore
induction of cell therapy can provide better solutions to the patient at the marginally lower cost.
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cell-
therapy-manufacturing-market-1728
Cell Therapy Manufacturing Market - Competitive Insights
The key player operating in the global cell therapy manufacturing market include, Pharmicell,
Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH,
Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris
Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate,
Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS,
MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec. Key players are adoption
growth strategies such as collaborations, introduction of new technologies and devices to maintain
dominant position in the market. For instance, in 2014, ViaCyte, Inc. successfully implanted VC-01
an embryonic stem cell derived islet for the treatment of type 1 diabetes.
Cell Therapy Manufacturing Market Taxonomy
On the basis of therapy type, the global cell therapy manufacturing market is segmented into:
•Allogeneic Cell Therapy
•Autologous Cell Therapy
On the basis of technology, the global cell therapy manufacturing market is segmented into:
•Somatic Cell Technology
•Cell Immortalization Technology
•Viral Vector Technology
•Genome Editing Technology
•Cell Plasticity Technology